Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Cerca in Study Connect
  • NCT07325136

Recruiting

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer - CA258-0001

Aggiornato: 17 febbraio, 2026   |   ClinicalTrials.gov.

Stampi il riassunto semplice

STA PRENDENDO IN CONSIDERAZIONE QUESTA SPERIMENTAZIONE?
Stampi questa pagina e la guida alla sperimentazione da utilizzare come supporto nel colloquio con il Suo medico.
Utilizzi la Guida per i partecipanti allo studio per esplorare il processo di partecipazione a una sperimentazione clinica. Comprenda i fattori chiave da considerare prima di decidere e pensi alle domande da porre al Suo team di professionisti sanitari.
Stampi questa pagina CA258-0001
Scarichi la Guida per i partecipanti allo studio

SELEZIONI UNA LINGUA

Dettagli della sperimentazione

  • Phase 1/Phase 2

    Fase

  • Sesso

  • 18+

    Fascia d'età

  • 7

    Sede/i

  • Recruiting

Opzioni di trattamento

Bracci dello studio
INTERVENTO ASSEGNATO
Experimental: Part 1A: BMS-986525 Monotherapy Dose Escalation
Drug: BMS-986525
Experimental: Part 1B: BMS-986525 Combination with Nivolumab Dose Escalation
Drug: BMS-986525, Nivolumab
Experimental: Part 2A: BMS-986525 Monotherapy Dose Expansion
Drug: BMS-986525
Experimental: Part 2B: BMS-986525 Combination with Nivolumab Dose Expansion
Drug: BMS-986525, Nivolumab

Principali criteri di idoneità

Inclusion Criteria - Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC). - Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines. - In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy. Exclusion Criteria - Participants must not have any untreated CNS metastases. - Participants must not have an active, known or suspected autoimmune disease. - Participants must not have had a prior organ or tissue allograft. - Other protocol-defined Inclusion/Exclusion criteria apply.

Ti consigliamo vivamente di contattare BMS per segnalare gli effetti collaterali (eventi avversi)
Qui vengono definiti gli effetti collaterali (eventi avversi) e altri eventi da segnalare
Segnala effetti collaterali (eventi avversi) o reclami sulla qualità del prodotto: informazioni mediche